Biologic Therapies for Type 2 Inflammatory Diseases: A Bibliometric Analysis of Publication Trends and Intellectual Structure

Mehmet Emin Gerek; Tuğba Önalan

doi:10.18621/eurj.1821314

Biologic Therapies for Type 2 Inflammatory Diseases: A Bibliometric Analysis of Publication Trends and Intellectual Structure

Abstract

Objectives: To comprehensively analyze the scientific literature (2005–2025) on biologic agents for Type 2 inflammatory diseases, including Severe Asthma (SA), Atopic Dermatitis (AD), and chronic rhinosinusitis with nasal polyps (CRSwNP). This study aimed to identify publication trends, thematic clusters, collaboration networks, and the field's intellectual foundation.

Methods: A bibliometric analysis was performed using data from the Web of Science (WoS) Core Collection (retrieved October 27, 2025). VOSviewer software was used to analyze co-occurrence networks (based on Author Keywords) and map collaborations.

Results: A total of 7,339 publications were analyzed. A significant acceleration in publishing occurred after 2017. The most productive countries were the USA (n=2,346), Italy (n=1,149), and the UK (n=936). Thematic analysis identified three distinct clusters: AD, SA, and CRSwNP. The intellectual foundation of the field is built upon highly cited phase 3 clinical trials (e.g., mepolizumab, dupilumab, benralizumab) published in top-tier journals (NEJM, The Lancet).

Conclusions: The research landscape for Type 2 biologics has grown rapidly since 2017, driven by clinical validation in landmark trials. The field's focus is evolving from demonstrating clinical efficacy toward mechanism-based personalized medicine and biomarker identification.

Keywords

Ethical Statement

This study was approved by the Chief Physician's Office of Necmettin Erbakan University Faculty of Medicine Hospital (date: 11.11.2025). This study was conducted using a publicly available and anonymized dataset, such as the Web of Science. As the data is publicly accessible and does not contain any patient-identifying information, institutional review board (IRB) approval was not required for this study. The study was conducted in accordance with the principles of the Declaration of Helsinki.

References

1. Maspero J, Adir Y, Al-Ahmad M, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8(3):00576-2021. doi: 10.1183/23120541.00576-2021.
2. Matsunaga K, Katoh N, Fujieda S, Izuhara K, Oishi K. Dupilumab: Basic aspects and applications to allergic diseases. Allergol Int. 2020;69(2):187-196. doi: 10.1016/j.alit.2020.01.002.
3. Ramírez-Jiménez F, Pavón-Romero GF, Velásquez-Rodríguez JM, et al. Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future. Pharmaceuticals (Basel). 2023;16(2):270. doi: 10.3390/ph16020270.
4. Canonica GW, Bourdin A, Peters AT, et al. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases. J Allergy Clin Immunol Pract. 2022;10(6):1515-1526. doi: 10.1016/j.jaip.2022.02.026.
5. Hellings PW, Verhoeven E, Fokkens WJ. State-of-the-art overview on biological treatment for CRSwNP. Rhinology. 2021;59(2):151-163. doi: 10.4193/Rhin20.570.
6. De Santis S, Galassi S, Cambi J. Clinical Effects and Response Time of Biological Drugs in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience. Laryngoscope. 2025;135(5):1628-1635. doi: 10.1002/lary.31948.
7. Colque-Bayona M, Hernández-Cano N, Tomás-Pérez M, Caballero T, Quirce S, Domínguez-Ortega J. Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. J Asthma. 2024;61(7):762-765. doi: 10.1080/02770903.2023.2300712.
8. Gore MR, Fung E, Tao M. An Analysis of Biologic Therapies in Patients With Asthma and Chronic Rhinosinusitis. Cureus. 2022;14(10):e30017. doi: 10.7759/cureus.30017.

9. Förster-Ruhrmann U, Stergioudi D, Szczepek AJ, et al. A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics. World Allergy Organ J. 2023;16(2):100746. doi: 10.1016/j.waojou.2023.100746.
10. Santus P, Saad M, Casartelli A, et al. Improvement in health-related quality of life questionnaires with biologic treatment in severe asthma and comorbid chronic rhinosinusitis with or without nasal polyposis: a real-life experience. Ann Med. 2024;56(1):2407523. doi: 10.1080/07853890.2024.2407523.
11. Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023-1042. doi: 10.1111/all.14221.
12. Liu Z, Yao Y, Xie H, et al. Visual and bibliometric analysis of chronic rhinosinusitis and nasal polyps. J Allergy Clin Immunol Glob. 2024;3(2):100211. doi: 10.1016/j.jacig.2024.100211.
13. Bignold RE, Busby H, Holloway J, Kasu A, Sian S, Johnson JR. Biologic therapies targeting type 2 cytokines are effective at improving asthma symptoms and control-a systematic review and meta-analysis. J Allergy Clin Immunol Glob. 2024;4(1):100374. doi: 10.1016/j.jacig.2024.100374.
14. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-1207. doi: 10.1056/NEJMoa1403290.
15. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783-800. doi: 10.1016/s0140-6736(17)33311-1.
16. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-2348. doi: 10.1056/NEJMoa1610020.
17. Caminati M, De Corso E, Ottaviano G, et al. Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps. Curr Allergy Asthma Rep. 2024;24(1):11-23. doi: 10.1007/s11882-023-01118-6.
18. Jia N, Jin M, Liu Y, et al. The management of type 2 inflammatory respiratory diseases: a Chinese expert consensus [2024]. J Thorac Dis. 2025;17(4):1807-1831. doi: 10.21037/jtd-2024-2092.
19. Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486-2496. doi: 10.1056/NEJMoa1804092.
20. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1.
21. Lommatzsch M, Blumchen K, Beck LA, et al. Roads to remission: evolving treatment concepts in type 2 inflammatory diseases. EClinicalMedicine. 2025;80:103050. doi: 10.1016/j.eclinm.2024.103050.
22. Fokkens WJ, Viskens AS, Backer V, et al. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology. 2023;61(3):194-202. doi: 10.4193/Rhin22.489.
23. Senna G, Micheletto C, Piacentini G, et al. Multidisciplinary management of type 2 inflammatory diseases. Multidiscip Respir Med. 2022;17(1):813. doi: 10.4081/mrm.2022.813.
24. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523-538. doi: 10.1007/s11192-009-0146-3.
25. Jia Y, Chen H, Liu J, Wang X, Guo R, Wang X. Exploring network dynamics in scientific innovation: collaboration, knowledge combination, and innovative performance. Front Phys. 2024;12:1492731. doi: 10.3389/fphy.2024.1492731.
26. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115-2127. doi: 10.1016/s0140-6736(16)31324-1.
27. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128-2141. doi: 10.1016/s0140-6736(16)31322-8.
28. Porsbjerg CM, Townend J, Bergeron C, et al. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma. Front Immunol. 2024;15:1361891. doi: 10.3389/fimmu.2024.1361891.
29. Nopsopon T, Lassiter G, Chen ML, et al. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. J Allergy Clin Immunol. 2023;151(3):747-755. doi: 10.1016/j.jaci.2022.11.021.
30. Chen Y, Wang L, Xie J. Combining Dual Biologics Therapy for Severe Asthma: A Series of Ten Cases. J Asthma Allergy. 2025;18:507-517. doi: 10.2147/JAA.S507008.
31. Lipworth BJ, Greig R, Chan R, Kuo CR, Jackson C. Head-To-Head Comparison of Biologic Efficacy in Asthma: What Have We Learned? Allergy. 2025;80(5):1226-1241. doi: 10.1111/all.16537.

Details

Primary Language

English

Subjects

Allergy

Journal Section

Research Article

Authors

Mehmet Emin Gerek ^*
0000-0003-4792-0544
Türkiye

Tuğba Önalan
0000-0003-2427-5925
Türkiye

Early Pub Date

December 25, 2025

Publication Date

February 1, 2026

Submission Date

November 10, 2025

Acceptance Date

December 22, 2025

Published in Issue

Year 2026 Volume: 12 Number: 2

DOI

https://doi.org/10.18621/eurj.1821314

IZ

https://izlik.org/JA33JR34WN

Cite

RIS / Bibtex

AMA

1.Gerek ME, Önalan T. Biologic Therapies for Type 2 Inflammatory Diseases: A Bibliometric Analysis of Publication Trends and Intellectual Structure. Eur Res J. 2026;12(2):235-248. doi:10.18621/eurj.1821314